NCT04389762

Brief Summary

The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started Jun 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 4, 2019

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

April 30, 2020

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 13, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 15, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 13, 2020

Completed
5 years until next milestone

Results Posted

Study results publicly available

June 25, 2025

Completed
Last Updated

August 17, 2025

Status Verified

July 1, 2025

Enrollment Period

11 months

First QC Date

April 30, 2020

Results QC Date

November 6, 2024

Last Update Submit

July 30, 2025

Conditions

Outcome Measures

Primary Outcomes (5)

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS)

    The UPDRS scores is a rating tool used to gauge the course of Parkinson's disease in patients. The minimum total score possible is 0 and the maximum total score possible is 199. Higher values represent a worse outcome.

    Baseline to Week 12 assessed on medication

  • Change in Unified Parkinson's Disease Rating Scale Part III (UPDRSIII) "OFF" Period

    The UPDRS III scores is subscores of UPDRS, it indicates motor function of PD symptoms. The minimum possible total score is 0 and the maximum possible total score is 108. Higher values represent a worse outcome.

    Baseline to Week 12 assessed off medications

  • Change in Unified Parkinson's Disease Rating Scale Part III (UPDRSIII) "ON" Period

    The UPDRS III scores is subscores of UPDRS, it indicates motor function of PD symptoms. The minimum possible total score is 0 and the maximum possible total score is 108. Higher values represent a worse outcome.

    Baseline to Week 12 assessed on medications

  • Change in Patient "ON-OFF" Diary Recording "OFF" Period

    "ON-OFF" motor fluctuations are rapid changes in mobility during which PD patients report sudden shifts from adequate mobility to mobility, usually within a few seconds or minutes. The 24-hour diary is divided into 30-minute sections and only mark one answer for each half hour period. It is to know how much time each patient spends in the different Parkinson's states. Higher hours in "OFF" period represent better outcome.

    Record for 3 consecutive days prior to Baseline and Week 12 visits by patient-self

  • Change in Patient "ON-OFF" Diary Recording "ON" Period

    Outcome Measure Description: "ON-OFF" motor fluctuations are rapid changes in mobility during which PD patients report sudden shifts from adequate mobility to mobility, usually within a few seconds or minutes. The 24-hour diary is divided into 30-minute sections and only mark one answer for each half hour period. It is to know how much time each patient spends in the different Parkinson's states. Higher hours in "ON" period represent worse outcome.

    Record for 3 consecutive days prior to Baseline and Week 12 visits by patient-self

Secondary Outcomes (3)

  • Change in Nonmotor Symptoms: 30-item Screening Questionnaire (NMS-Quest) Total Score

    Baseline to Week 12 assessed on Medication

  • Change in The Parkinson's Disease Questionnaire (PDQ-39)

    Baseline to Week 12 assessed on Medication

  • Patient Global Impression of Change (PGI-C)

    Week 12 assessed on Medication

Study Arms (1)

PS128

EXPERIMENTAL

daily ingestion of Lactobacillus plantarum PS128 capsules

Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128

Interventions

daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)

PS128

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with idiopathic Parkinson's Disease
  • According to the record of ON / OFF diary for 3 consecutive days, the patient's daily off periods must be more than 3 hours a day.
  • Between ages of 40-80 years old.

You may not qualify if:

  • Patients on antibiotics within the preceding one month
  • Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
  • Have undergone surgery of liver, bladder, or gastrointestinal tract
  • Have current or history of inflammatory bowel disease
  • Have history of cancer
  • Known allergy to probiotics
  • Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
  • Have received deep brain stimulation
  • Patients receiving artificial enteral or intravenous nutrition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Professor Lu Neurological Clinic

Taoyuan, Guishan Dist., 333, Taiwan

Location

Related Publications (1)

  • Lu CS, Chang HC, Weng YH, Chen CC, Kuo YS, Tsai YC. The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study. Front Nutr. 2021 Jun 30;8:650053. doi: 10.3389/fnut.2021.650053. eCollection 2021.

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Results Point of Contact

Title
Professor Lu
Organization
Professor Lu Neurological Clinic

Study Officials

  • Chin-Song Lu, MD

    Professor Lu Neurological Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 30, 2020

First Posted

May 15, 2020

Study Start

June 4, 2019

Primary Completion

May 13, 2020

Study Completion

June 13, 2020

Last Updated

August 17, 2025

Results First Posted

June 25, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations